Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: Potential utility as antipsychotic medications

Drake Morgan a,⁎, Krishnakanth Kondabolu b, Allison Kuipers a, Rajeev Sakhija b,1, Kimberly L. Robertson c, Neil E. Rowland c, Raymond G. Booth b,d

a Department of Psychiatry, College of Medicine, University of Florida, Gainesville, FL, USA
b Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
c Department of Psychology, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL, USA
d Center for Drug Discovery, Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA

Abstract

Background: Desired serotonin 5HT2 receptor pharmacology for treatment of psychoses is 5HT2A antagonism and/or 5HT2C agonism. No selective 5HT2A antagonist has been approved for psychosis and the only approved 5HT2 agonist (for obesity) also activates 5HT2A and 5HT2B receptors, which can lead to clinical complications. Studies herein tested the hypothesis that a dual-function 5HT2A antagonist/5HT2C agonist that does not activate 5HT2B receptors would be suitable for development as an antipsychotic drug, without liability for weight gain.

Methods: The novel compounds (+)- and (-)-trans-4-(4′-chlorophenyl)-N,N-dimethyl-2-amino tetralin (p-CI-PAT) were synthesized, characterized in vitro for affinity and functional activity at human 5HT2 receptors, and administered by intraperitoneal (i.p.) and oral (gavage) routes to mice in behavioral paradigms that assessed antipsychotic efficacy and effects on feeding behavior.

Results: (+)- and (-)-p-CI-PAT activated 5HT2C receptors, with (+)-p-CI-PAT being 12-times more potent, consistent with its higher affinity across 5HT2 receptors. Neither p-CI-PAT enantiomer activated 5HT2A or 5HT2B receptors at concentrations up to 300-times greater than their respective affinity (Ki), and (+)-p-CI-PAT was shown to be a 5HT2A competitive antagonist. When administered i.p. or orally, (+)- and (-)-p-CI-PAT attenuated the head-twitch response (HTR) in mice elicited by the 5HT2 agonist (-)-2,5-dimethoxy-4-iodoamphetamine (DOI) and reduced intake of a highly palatable food in non-food-deprived mice, with (+)-p-CI-PAT being more potent across behavioral assays.

Conclusions: The novel in vitro pharmacology of (+)-p-CI-PAT (5HT2A antagonism/5HT2C agonism without activation of 5HT2B) translated in vivo to an orally-active drug candidate with preclinical efficacy to treat psychoses without liability for weight gain.

1 Introduction

Brain dopamine and serotonin systems have long been thought to be involved in the pathophysiology and pharmacotherapy of schizophrenia and other psychoses. For example, the dopamine hypothesis of schizophrenia arose from observations that the first relatively safe and effective antipsychotic drugs, the phenothiazines (e.g., chlorpromazine) in the early 1950s, affect brain dopamine metabolism (Carlsson and Lindquist, 1963). Neuroleptics such as chlorpromazine and the butyrophenone haloperidol “take hold” (lepsis) of the central nervous system (CNS) to suppress movement as well as other behavior, and resulting debilitating extrapyramidal movement side effects are implicit in the clinical definition of neuroleptic antipsychotic drugs. Newer antipsychotic drugs, without substantial risk of extrapyramidal effects, are referred to as “atypical” and have a mechanism other than (or in addition to) postsynaptic D2-type receptor blockade. Such second generation antipsychotics include the dibenzodiazepines (e.g., clozapine, olanzapine) that have less potential for extrapyramidal side effects and have significant activity at brain serotonin 5HT2-type receptors (as well as adrenergic α1/2, muscarinic, and/or histamine H1 receptors) in addition to activity at D2-type receptors (Meltzer, 1996; Meltzer et al., 2003; Seeman, 2002; Tandon and Fleischhacker, 2005). Speculatively, a relatively selective 5HT2A antagonist might function as a useful...
antipsychotic medication. Several new potential medications have been developed as antipsychotic drugs that are selective 5HT2A antagonists/inverse agonists, however little success in the clinic has been observed (clinicaltrials.gov reveals no ongoing trials using selective 5HT2A compounds) suggesting that selective blockade of 5HT2A alone may not represent the ideal pharmacological profile.

One side effect of atypical antipsychotics is weight gain (Coccurello and Moles, 2010; Lieberman et al., 2005; Maayan and Massey, 2011; Roerig et al., 2011). In fact, most atypical antipsychotic drugs that are 5HT2A antagonists/inverse agonists are also 5HT2C receptor antagonists/inverse agonists (Herrick-Davis et al., 2000; Rauser et al., 2001). Preclinical data suggest that activation of 5HT2C receptors is associated with decreased eating and weight loss (Hayashi et al., 2003; Hewitt et al., 2002; Rowland et al., 2008).

In addition, one neuropharmacological consequence of 5HT2A activation is preferential decreases in mesolimbic compared to nigrostriatal dopamine levels (Di Giovanni et al., 2000; Marquis et al., 2007) which may suggest an improved antipsychotic effect without motor-related side effects. Thus, the desirable serotonergic pharmacology for an antipsychotic medication is 5HT2A antagonism and 5HT2C agonism. It should be noted that there is no clinical tolerance for activation of 5HT2B receptors as this is associated with severe cardiac valvulopathy and other cardiotoxic effects (Elangbam, 2010; Roth, 2007).

We previously reported that a novel phenylaminotetralin, (−)-(2S, 4R)-trans-4-phenyl-N,N-dimethyl-2-aminotetralin (PAT; Fig. 1), was a 5HT2C agonist with 5HT2A and 5HT2B inverse agonist/antagonist activity (Booth et al., 2009) that demonstrated preclinical antipsychotic activity (Booth et al., 2008) and decreased intake of a highly palatable food in non-food-deprived mice (a binge eating model) (Rowland et al., 2008). The PAT molecular scaffold (Fig. 1) has two chiral centers, thus, there are a pair of cis- and trans-enantiomers, for a total of four stereoisomers. For PAT, the (−)-(2S, 4R)-trans enantiomer is most potent and efficacious regarding binding and function across 5HT2 receptor subtypes (Booth et al., 2009). Here we report on two novel analogs that contain a chlorine moiety at 4’- or para-position of the c(4) phenyl group on the PAT parent compound, (−)-(2R, 4S)- and (−)-(2S, 4R)-trans-4-(4’-chlorophenyl)-N,N-dimethyl-2-aminotetralin (p-CIP-PAT; Fig. 1). Computational chemistry studies suggest that the electronegative chlorine atom at the para-position of the PAT phenyl ring provides an electronic and steric symmetry that modulates affinity and function at 5HT2 receptors (Cordova-Sintjago et al., 2011, 2012). Here we report the in vitro 5HT2 affinity and function of (−)- and (−)-p-CIP-PAT and assess its in vivo 5HT2 activity after intraperitoneal (i.p.) and oral (p.o.) administration in behavioral paradigms sensitive to the antipsychotic and “anti-binge-eating” effects of potential therapeutic.

2. Methods

2.1. Chemicals

The radioligands [3H]-mesulergine and [3H]-ketanserin were purchased from Perkin–Elmer Life Science (Boston, MA). The 5HT2 agonist (−)-2.5-dimethoxy-4-iodoamphetaminehydrochloride (DOI) was generously supplied by the National Institute on Drug Abuse. The (−)(2S, 4R)- and (−)(2R, 4S)-trans enantiomers of 4’-(4’-chlorophenyl)-N,N-dimethyl-2-aminotetralin (p-CIP-PAT) hydrochloride were synthesized by Dr. Rajaev Sakhuja at the University of Florida Department of Medicinal Chemistry (Morgan et al., 2012) and a full description of the methods and physical characterization will be reported elsewhere. Briefly, 4’-(4’-chlorophenyl)tetrabenzo-2-ol phenylacetae was synthesized from 4-chlorostyrene and tri- fluoracetyl phenylacetylene anhydride via cascade Friedel–Crafts cycli-acylation, enolization, and O-acetylation following our published procedures (Vincek and Booth, 2009). The tetrabenzo-2-ol phenylacetae was reduced with sodium borohydride at 50°C in methanol to yield the cis-tetrrol (major) that was converted to the corres- ponding cis-tosylate using p-tosyl chloride in pyridine at room temperature. The cis-tosylate on amination with aqueous dimethylamine solution in a sealed tube at 80°C for 24 h yielded racemic trans-4’-(4’-chlorophenyl)-N,N-dimethyl-2-aminotetralin (high resolution mass spectrometry results for C15H12CIN [M + H]+: 286.1364; calculated: 286.1363). The trans racemic p-CIP-PAT mixture was resolved to the (−)- and (+)-enantiomers using chiral stationary-phase preparative HPLC (MeOH/EtOH:1-POH:2-POH:Hexanes [5:5:5:80] 0.2% TEA modifier; flow rate = 1.5 mL/min; t1 = 10.9, t2 = 12.8). The water-soluble (+)- and (−)-p-CIP-PAT hydrochloride (HCl) salts were prepared [p(CIP)Cl2] = 45.5 and 46.0 in CH2Cl2, respectively) and used in all in vitro and in vivo pharmacological experiments.

2.2. Clonal cell culture and transfection

Human embryonic kidney 293 cells (HEK, ATCC CRL-1573) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 5% fetal bovine serum and 1% penicillin-streptomycin. Cells were grown in a humidified incubator at 37°C with 5% carbon dioxide. The cDNAs encoding the human 5HT2A, 5HT2B and 5HT2C receptors were obtained from Open Biotech (Rolla, MO). HEK-293 cells were grown to 90% confluence in DMEM (10-013-CV, Mediatech, Manassas, VA), supplemented with 5% dialyzed fetal bovine serum (FBS). Incubation of radioreceptor binding assay mixtures was for 1.0 h at 37°C. Membranes were then collected in 50 mM Tris, 10 mM MgCl2, 1.5 mL/min; 0.2% TEA modi- fier; flow rate = 1.5 mL/min; t1 = 10.9, t2 = 12.8). The water-soluble (+)- and (−)-p-CIP-PAT hydrochloride (HCl) salts were prepared [p(CIP)Cl2] = 45.5 and 46.0 in CH2Cl2, respectively) and used in all in vitro and in vivo pharmacological experiments.

2.3. Radioreceptor competition binding assays

Radioligand competitive displacement binding assays were performed in 96-well plates, using 3–5 μg of protein from membrane samples. Cells transfected to laboratory methods used previously (Booth et al., 2009). Radioligands were included in assay mixtures at Ki concentration, i.e., 2.0 nM [3H]-ketanserin (5HT2A re- ceptors), 1.95 nM [3H]-mesulergine (5HT2B receptors), or 1.4 nM [3H]-mesulergine (5HT2C receptors). Non-specific binding was determined in the presence of 10 μM mianserin for all 5HT2 receptors. Incubation of radioreceptor binding assay mixtures was for 1.0 h at 37°C, with termination by rapid filtration through Whatman GF/B filters using a 96-well cell harvester (Tomtec, Hamden, CT) and subsequently washed five times with 50 mM Tris–HCl at room temperature. Filters containing bound [3H]-radioligand were dried, placed in vials containing 2 ml scintillation cocktail (ScintVerse), allowed to equilibrate overnight, and then counted for 1 h using a Beckman Coulter LS6500 counter. Binding experi- mental conditions were performed in triplicates, and each experiment was per- formed a minimum of three times. Data were analyzed using nonlinear regression curve-fitting algorithms in GraphPad Prism, 5.03 for Windows (San Diego, CA). Data points were limited to eight, thus Hill slopes were not calculated (Motulsky and Christopoulos, 2003); data fit the using the “one site fit” Km model that constrains the Hill slope to 1.0. Ligand affinity is expressed as Ki values by conversion of the IC50 data using the equation Ki = IC50([1 + L]/Ki) where L is the concentration of radio- ligand (Cheng and Prusoff, 1973). Comparisons of Ki values were performed using the two-way ANOVA with Bonferroni's post-hoc test. Differences were considered sta- tistically significant when the p-value was less than 0.05.

2.3.2. Measurement of PLC activation and [3H]-IP formation

Functional activity was measured as PLC activation and [3H]-IP formation in HEK cells transiently expressing 5HT2A, 5HT2B or 5HT2C receptors (Booth et al., 2009;
2.4. In vivo behavioral pharmacology

2.4.1. Subjects

C57Bl/6j male mice were obtained from Harlan (food studies) or Jackson (HTR) Laboratories at approximately 8 weeks of age, and allowed to acclimate to the temperature- and humidity-controlled colony room for at least 1 week prior to testing. Mice were singly- or pair-housed in standard cages and allowed unlimited access to laboratory chow and water. Experiments were conducted at approximately the middle of the light phase (lights on at 6 am, and lights off at 6 pm). All compounds were dissolved in sterile saline prior to behavioral testing, and administered in a volume of 0.01 mL/g body weight. All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals, as promulgated by the National Institutes of Health, and were approved by the University of Florida’s Institutional Animal Care and Use Committee.

2.4.2. DOI-elicited head-twitch response and locomotor activity

On the day of testing, mice were habituated to the testing room for approximately 30 min. Testing consisted of administration (i.p.) of sterile saline or a particular dose of (+)- or (-)-p-Cl-PAT. Ten minutes later, mice were administered (-)-DOI or sterile saline. Ten minutes later, mice were individually placed into a clear Plexiglas chamber (17” x 12” x 12”). Following oral administration of the PAT analog or saline, 20 min elapsed before administration of (-)-DOI. Head-twitch responses (HTRs), defined as a clear, rapid, and discrete, back and forth rotation of the head, were counted by an experimenter. Data was expressed as mean ± SEM of at least three independent experiments each performed in triplicate.

Fig. 2. Representative radioligand competition binding curves for (+)- and (-)-p-Cl-PAT enantiomers at human 5HT2 receptors expressed in human embryonic kidney cells (HEK) cells. Data are represented as mean ± SEM of at least three independent experiments each performed in triplicate.

3. Results

3.1. In vitro molecular pharmacology of (+)- and (-)-p-Cl-PAT at 5HT2 receptors

3.1.1. Affinity

Both (+)- and (-)-p-Cl-PAT potently displaced [3H]-ketanserin from 5HT2A and 5HT2B receptors or [3H]-mesulergine from 5HT2C receptors (Fig. 2, data summarized in Table 1), with (+)-p-Cl-PAT having significantly higher affinity (Kᵢ) than (-)-p-Cl-PAT at 5HT2A, 5HT2B, and 5HT2C receptors (F₂,₁ = 5.23, F₁,₂ = 92.04, and F₂,₁ = 12.17, respectively; p < 0.05 for all 5HT2 subtypes). In contrast to its function (see below), (+)-p-Cl-PAT affinity was not different (p > 0.05) at the 5HT2 receptor subtypes, whereas, (-)-p-Cl-PAT bound with higher affinity (p < 0.05) at 5HT2C compared to 5HT2A and 5HT2B receptors.

3.1.2. Function

Fig. 3 shows functional activity of 5HT in comparison to (+)- and (-)-p-Cl-PAT at 5HT2A, 5HT2B and 5HT2C receptors, as measured by activation of PLC and [3H]-IP formation. Consistent with the literature (e.g., Booth et al., 2009), the endogenous agonist serotonin (5HT) had an EC₅₀ value of 106 ± 19 nM, 50 ± 10 nM and 10 ± 3 nM at 5HT2A, 5HT2B, and 5HT2C receptors, respectively. Neither (+)- nor (-)-p-Cl-PAT activated 5HT2A or 5HT2B receptors, even at 10 μM concentration (125–300-times Kᵢ values summarized in Table 1). In contrast, both (+)- and (-)-p-Cl-PAT were partial agonists (compared to 5HT) at the 5HT2C receptor. Consistent with its higher affinity (Table 1), the (+)-p-Cl-PAT enantiomer was about 12-times more potent (EC₅₀ = 140 ± 20 nM) (p < 0.0001) than (-)-p-Cl-PAT (EC₅₀ = 1650 ± 149 nM), however, there was no difference (p > 0.05) in efficacy (Emax). Additional functional studies...
undertaken with the more potent (+)-p-Cl-PAT enantiomer confirmed competitive antagonism \( \text{pA}_2 = 6.21 \pm 0.55 \) with respect to 5HT activation of 5HT2A-mediated \([3H]\)-IP formation.

### 3.2. In vivo behavioral pharmacology

#### 3.2.1. Head-twitch responses

When (+)-DOI was administered (preceded by a saline injection), there was a dose-dependent increase in the number of head-twitch responses (HTRs) observed during the 10-min session (Fig. 4, left panel). The number of head-twitches increased from an average of 1.25 following saline administration, to 6, 22, and 45 head-twitches following 0.1, 0.3, and 1.0 mg/kg (+)-DOI \((F_{9,28} = 42.3; \ p < 0.001; \text{significant increases at } 0.3 \text{ and } 1.0 \text{ mg/kg DOI})\). Both the (+) and (−) enantiomers of p-Cl-PAT failed to alter the number of HTRs when administered with saline (range from 0 to 2.5 across doses; Fig. 4, left panel). Subsequent experiments examined the effects of p-Cl-PAT pretreatment before administration of 1 mg/kg (−)-DOI (Fig. 4, right panel). Both isomers produced a dose-dependent attenuation of the DOI-elicited HTR such that following pretreatment with 30 mg/kg of the (+) and (−) enantiomers, there were 3.3 and 13 responses, respectively. ANOVA \((F_{6,27} = 15.66; \ p < 0.001)\) revealed that 10 and 30 mg/kg doses of (+) and 30 mg/kg of (−)-p-Cl-PAT resulted in significantly lower levels of HTRs relative to saline pretreatment. The dose required to produce a 50% attenuation (ED50 value ± 95% CI) of the DOI-elicited response was 8.2 (5.4–12.4) and 20.1 (14.0–28.8) mg/kg for the (+) and (−) enantiomers, and there was a significant difference between the dose–effect curves of (+) and (−)-p-Cl-PAT \((F_{1,23} = 17.49; \ p < 0.001)\). The effects of 30 mg/kg of each enantiomer and the racemic combination were assessed following oral administration (via gavage). Following oral saline administration, (−)-DOI (1.0 mg/kg) elicited an average of 37.5 HTRs (Fig. 5). Oral administration of (+), (−), and (±)-p-Cl-PAT (30 mg/kg) resulted in an attenuated response to DOI: 8.5, 18.25, and 13.25 HTRs respectively. Each dose combination resulted in fewer HTRs \((F_{3,16} = 31.1; \ p < 0.001)\) relative to saline pretreatment, and there was a statistically significant difference between the (+)- and (−)-enantiomers \(p = 0.038\).

#### 3.2.2. Locomotor activity

During all behavioral sessions, levels of overall activity were recorded and are shown in Table 2. Although, there appeared to be a

<table>
<thead>
<tr>
<th>p-Cl PAT</th>
<th>5HT2A</th>
<th>5HT2B</th>
<th>5HT2C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki ± SEM (nM)</td>
<td>Function</td>
<td>Ki ± SEM (nM)</td>
<td>Function</td>
</tr>
<tr>
<td>(+)-trans</td>
<td>42 ± 6.0</td>
<td>No activation(^*)</td>
<td>80 ± 10</td>
</tr>
<tr>
<td>(−)-trans</td>
<td>240 ± 32</td>
<td>No activation(^*)</td>
<td>300 ± 30</td>
</tr>
</tbody>
</table>

\(^*\) No activation of PLC/IP formation at 10 μM.
slight increase in activity following administration of 1.0 mg/kg 
(−)-DOI, there were no statistically significant differences following 
any drug alone, relative to saline. The highest doses of (+) and (−) 
-Cl-PAT administered as a pretreatment to 1.0 mg/kg (−)-DOI 
resulted in statistically significant lower levels of activity relative to 
saline pretreatment (p values < 0.05). Oral administration of p-Cl-
PAT failed to alter locomotor activity when compared to oral saline 
pretreatment.

3.2.3. Palatable meal eating

Mice were provided 10 Fruit Crunchies daily, and ate on average, 
5.2 (±0.1) pellets during the baseline 30-min sessions and 5.0 
(±0.25) pellets following administration of vehicle. Both enanti-
omers produced a dose-dependent attenuation of the number of 
pellets consumed such that following pretreatment with 24 mg/kg 
of the (+) and (−) enantiomers, eating was statistically significa-
cantly decreased to 15.9% (±6.4) and 36.4% (±9.1) of baseline levels,
respectively (Fig. 6; F_{6,58} = 33.6, p < 0.001). The doses required to 
produce a 50% attenuation (ED50 value ± 95% CL) of consumption 
was 14.8 (11.8−18.7) and 21.3 (18.5−24.4) mg/kg for the (+) and (−) 
enantiomers, and there was a significant difference between the 
dose–effect curves of (+) and (−)-p-Cl-PAT (F_{1,42} = 10.2, p < 0.003).

4. Discussion

It is implicit from preclinical and clinical literature and practice 
that optimal 5HT2 pharmacology desired for antipsychotic drug 
efficacy without liability for weight-gain or other untoward side 
effects (such as cardiopulmonary toxicity associated with 5HT2B 
activation) is absolutely-selective 5HT2A antagonism and/or 5HT2C
agonism. Accordingly, the unique multifunctional 5HT2 pharmacology (i.e., 5HT2A/2B antagonism together with 5HT2C agonism) demonstrated by (−)-(2S, 4R)-trans-PAT (Booth et al., 2009) appears to be optimal for development of 5HT2-based antipsychotic drugs without weight gain and other deleterious side effects. Based on computational and molecular modeling structure—activity studies, we predicted that the novel analog p-CI-PAT would demonstrate 5HT2 pharmacology similar to PAT, i.e. (pre)clinical relevant affinity at 5HT2A and 5HT2C receptors but specifically activate only 5HT2C receptors. Unexpectedly, stereoselectivity regarding 5HT2 affinity and functional activity was reversed for p-CI-PAT in comparison to PAT. Thus, the (+)-(2R, 4S)-trans-p-CI-PAT enantiomer had (pre)clinically-relevant high affinity across 5HT2 receptors, in comparison to the (−)-enantiomer, which had several-fold lower affinity. Likewise, functionally, the (+)-p-CI-PAT enantiomer was the more potent 5HT2 (partial) agonist. Importantly, however, (+)-p-CI-PAT did not activate 5HT2A or 5HT2B receptors (nor did the (−)-enantiomer) and was shown to competitively antagonize 5HT activation of 5HT2A-mediated activation of PLC and IP formation. These unexpected results concerning stereocchemistry impact on 5HT2 ligand affinity and function provide important information for computational and modeling studies regarding the 3-dimensional arrangement of 5HT2 receptor amino acids in the binding pocket. Results will be used to refine current 5HT2 receptor models based on homology to the β-adrenergic receptors (Cordova-Santiago et al., 2011, 2012) for accurate prediction of ligand interactions for drug discovery purposes. Nevertheless, here we identified (+)-p-CI-PAT as a new high affinity 5HT2 receptor ligand that potently and specifically activates 5HT2C and not 5HT2A or 5HT2B receptors, precisely the 5HT2-based pharmacology desired for antipsychotic activity, without liability for 5HT2-mediated toward side-effects such enhanced feeding behavior or cardiopulmonary toxicity.

To determine if the unique multifunctional 5HT2 receptor pharmacology of p-CI-PAT would translate in vivo to preclinical antipsychotic activity, we examined their ability to modulate the DOI-elicited HTR in mice. DOI-elicited HTRs have been purported to model a number of behavioral and pathological conditions including schizophrenia/psychosis, obsessive-compulsive disorders, tics associated with Tourette’s syndrome, and hallucinogenesis (Canal and Morgan, 2012). Similarities in the subjective effects of psychedelic hallucinogens and the perceptual and subjective effects associated with psychosis-related disorders (e.g. schizophrenia) suggested that the behavioral effects following administration of hallucinogenic compounds (e.g. DOI-elicited HTRs) could be a model of the “positive” symptoms (in particular, hallucinations) of schizophrenia (González-Maeso et al., 2008). In this regard, every effective antipsychotic medication used in humans is effective in attenuating the HTR elicited by DOI administration, including “typical” (primarily D2 antagonists) and “atypical” (5HT2/D2 antagonists) antipsychotics, as well as novel medications being investigated in clinical trials (e.g. glutamatergic compounds; clinicaltrials.gov). Although there are few ‘false negatives’ associated with this model as a “screen” for antipsychotic activity, there are examples of ‘false positives’ (i.e. drugs that work in the animal model and do not translate into effective antipsychotic compounds in humans). An important example is the relatively selective 5HT2A antagonist/inverse agonist M100907 which apparently failed in clinical trials for treating schizophrenia.

In fact, the in vitro 5HT2 molecular pharmacology of p-CI-PAT translates congruently in vivo, with the (+)-enantiomer being more potent than the (−)-enantiomer in the DOI-elicited HTR assay, and with the (+/-)-racemic mixture being intermediate between the two in potency. It is proposed here that activation of 5HT2C receptors (5HT2A antagonism is implicit) associated with the lead (+)-p-CI-PAT analog may enhance its potential as an antipsychotic drug given that 5HT2C activation preferentially decreases mesolimbic dopamine levels while sparing nigrostriatal dopamine cell activity and extracellular levels (Di Giovanni et al., 2000), a pharmacological profile suggesting antipsychotic effects without debilitating extrapyramidal side effects.

Another primary side effect of currently available antipsychotic medications is weight gain (Coccurello and Moles, 2010; Lieberman et al., 2005; Maayan and Correll, 2010; McCloughen and Foster, 2011). In addition to the adverse health effects associated with weight gain itself (National Task Force on the Prevention and Treatment of Obesity, 2000), patient weight gain dramatically decreases antipsychotic medication compliance (Weiden et al., 2004). There are conflicting data regarding the physiological mechanisms by which weight gain associated antipsychotic use occurs (Balt et al., 2011; Correll et al., 2011; Roerig et al., 2011), however it has been suggested that antagonism of 5HT2C receptor systems may be partially responsible. For example, atypical antipsychotics generally have clinically-relevant affinity at several neurotransmitter receptor types, including, adrenergic (α1 and α2), dopamine (D1, D3 and D4), histamine (H1), muscarinic, and serotonin (5HT1A, 5HT2A, 5HT2C, 5HT6 and 5HT7). While 5HT2A receptor antagonism is thought to contribute to the efficacy of atypical antipsychotic drugs, most, such as olanzapine, also are about equi-potent at blocking 5HT2C receptors, which could contribute to their propensity to cause weight gain. In contrast, compounds that activate 5HT2C receptors are thought to enhance satiety, decrease meal size, and decrease caloric intake by stimulating pro-opiomelanocortin secretion from arcuate nucleus neurons (and subsequent activation of melanocortin systems) (Heisler et al., 2003; Hewitt et al., 2002). Based on these and similar findings, there are drug discovery efforts toward a 5HT2C-specific agonist as a weight-loss medication (Halford et al., 2011), but, for now, only a 5HT2C-prefering antagonist (lorcaserin, Belviq) is available (Thomsen et al., 2008).

Preliminary off-target binding studies with (+) and (−)-p-CI-PAT have been undertaken and initial results suggest that, as for (−)-trans-PAT (Booth et al., 2009), these compounds have comparatively low ($K_i > 0.5 \mu M$) or very low ($K_i > 1 \mu M$) affinity for...


Cheng, Y., Prusoff, W.H., 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108.


